Therapeutic Class |
Antibiotic, Cephalosporin (Third Generation) |
Indications |
Treatment of susceptible acute, community-acquired pneumonia caused by S. pneumoniae or nonbeta-lactamase producing H. influenzae; acute uncomplicated gonorrhea caused by N. gonorrhoeae; uncomplicated skin and skin structure infections caused by S. aureus or S. pyogenes; acute otitis media caused by S. pneumoniae, H. influenzae, or M. catarrhalis; pharyngitis or tonsillitis; and uncomplicated urinary tract infections caused by E. coli, Klebsiella, and Proteus. |
Adult Doses |
Oral: Acute community-acquired pneumonia and bacterial exacerbations of chronic bronchitis: Uncomplicated gonorrhea (male and female) and rectal gonococcal infections (female): Uncomplicated urinary tract infection: Acute maxillary sinusitis: Pharyngitis/tonsillitis: Skin and skin structure: |
Pediatric Doses |
Oral: Acute otitis media: Acute maxillary sinusitis: Pharyngitis/tonsillitis: ≥12 years: Refer to adult dosing |
Doses in Renal impairment |
Clcr <30 mL/minute: Administer every 24 hours. Hemodialysis: Dose 3 times/week following dialysis. |
Contraindications |
Hypersensitivity to cefpodoxime, any component of the preparation , or other cephalosporins. |
Warnings / Precautions |
Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). |
Adverse Reactions |
Potentially Fatal: Pseudomembranous colitis; nephrotoxicity. Agranulocytosis, aplastic anemia, cholestasis, colitis, erythema multiforme, hemolytic anemia, hemorrhage, interstitial nephritis, toxic nephropathy, pancytopenia, renal dysfunction, seizure, serum-sickness reactions, Stevens-Johnson syndrome, superinfection, toxic epidermal necrolysis, urticaria, vaginitis |
Overdose Reactions |
Toxic symptoms may include nausea, vomiting, epigastric distress and diarrhoea. Haemodialysis or peritoneal dialysis may aid in the removal of cefpodoxime from the body, particularly if renal function is compromised. |
Drug Interactions |
Antacids or H2-blockers may decrease the absorption of cefpodoxime. Probenecid inhibits renal excretion. |
Lab Interactions |
Urinary glucose test by Benedict's and Fehling's tests solution may produce false-positive result. May induce a positive direct Coombs' test. |
Food Interactions |
Food delays absorption; cefpodoxime levels may be increased with food. |
Mechanism of Actions |
Cefpodoxime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly ; Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. |
Pharmacodynamics |
Absorption: Rapid and well absorbed (50%), acid stable; enhanced in the presence of food or low gastric pH Distribution: Good tissue penetration, including lung and tonsils; penetrates into pleural fluid Protein binding: 18% to 23% Metabolism: De-esterified in GI tract to active metabolite, cefpodoxime Half-life elimination: 2.2 hours; prolonged with renal impairment Time to peak: Within 1 hour Excretion: Urine (80% as unchanged drug) in 24 hours |
Monitoring |
Observe for signs and symptoms of anaphylaxis during first dose; give test dose. |
Administration |
Administer at proper / regular intervals to promote less variation in peak and trough serum levels. |
Pregnancy Category |
B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester. |
Lactation |
Enters breast milk (small amounts)/not recommended. |
Storage Conditions |
Oral: Store at 20-25°C. |
ATC Classification |
J01DD13 |
GenericPedia Classification |
|
Storage |
Oral: Store at 20-25°C. |
Available As |
|
Cefpodoxime
Post Review about Cefpodoxime Click here to cancel reply.
Cefpodoxime Containing Brands
Cefpodoxime is used in following diseases
Drug - Drug Interactions of Cefpodoxime
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.